NCT05152147Phase 3Active not recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Study sponsor: Jazz Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-07-15Actual
Enrollment · participants920Actual
Source updated2026-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 30 Sep 2026. After: 15 Jul 2026.

Check registry source

· 1 field changed

Primary completion date changed

Before: 31 Jul 2026. After: 30 Sep 2026.

Check registry source

· 1 field changed

Primary completion date changed

Before: 1 Dec 2025. After: 31 Jul 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview